FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106859275> ?p ?o ?g. }

• W2106859275 endingPage "400" @default.
• W2106859275 startingPage "395" @default.
• W2106859275 abstract "<h3>Background</h3> Recombinant interferon β (IFNβ) is a first-line therapy for relapsing-remitting multiple sclerosis (MS), with a proven effect on the inflammatory activity. Neutralising antibodies against IFNβ (NAbs) promote a loss of IFNβ bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. We investigated the contribution conferred by HLA alleles on the development of NAbs in independent cohorts of Southern Europe. <h3>Methods</h3> Serum NAbs from 610 MS patients with HLA-genotype data were evaluated by cytopathic effect assay: negative tests included at least one negative result (NAb titres<20 NU/mL) after 1 year treatment; NAb-titres ≥20 NU/mL were positive tests and NAb titres ≥150 NU/mL in any test were classified as high-titre positives. <h3>Results</h3> The combined presence of <i>DRB1*07/DQA1*</i>02 with A<i>*26</i> or <i>B*14</i> was found in 20% of patients with NAbs at high titres, but only in 5.4% of NAb-negative patients (p=0.00052, OR (95% CI) 4.34 (1.85 to 10.13)). The <i>DRB1*04:01</i> allele was also more frequently carried by patients with high titres of NAbs (10% vs 4.5%; p=0.046, OR (95% CI) 2.38 (0.93 to 5.92)). The alleles carried at a significantly lower frequency in patients with high persistent NAbs corresponded to the <i>A*11</i> allele (3.3% vs 13.8%; p=0.023, OR (95% CI) 0.22 (0.02 to 0.87)), as well as the <i>DRB1*03/DQA1*05/DQB1*02</i> haplotype (16.3% vs 26.8%; p=0.02, OR (95% CI) 0.53 (0.27 to 1.03)) and the <i>DRB1*13/DQA1*01:03/DQB1*06:03</i> haplotype (2.5% vs 9.1%; p=0.045, OR (95% CI) 0.25 (0.03 to 1.02)). <h3>Conclusions</h3> 50% of the studied MS patients carried some of the five independently associated HLA allele/allele combinations described in this work. This relevant percentage of patients could benefit a therapeutic decision." @default.
• W2106859275 created "2016-06-24" @default.
• W2106859275 creator A5003647254 @default.
• W2106859275 creator A5026572220 @default.
• W2106859275 creator A5029175418 @default.
• W2106859275 creator A5031171090 @default.
• W2106859275 creator A5035645353 @default.
• W2106859275 creator A5040342808 @default.
• W2106859275 creator A5042890325 @default.
• W2106859275 creator A5057965399 @default.
• W2106859275 creator A5070677379 @default.
• W2106859275 creator A5079962370 @default.
• W2106859275 creator A5084425257 @default.
• W2106859275 creator A5091751427 @default.
• W2106859275 date "2014-04-19" @default.
• W2106859275 modified "2023-10-17" @default.
• W2106859275 title "HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis" @default.
• W2106859275 cites W1967156553 @default.
• W2106859275 cites W1968558564 @default.
• W2106859275 cites W1969930449 @default.
• W2106859275 cites W1971968909 @default.
• W2106859275 cites W1984098314 @default.
• W2106859275 cites W1986173197 @default.
• W2106859275 cites W1987933122 @default.
• W2106859275 cites W2002905244 @default.
• W2106859275 cites W2015760526 @default.
• W2106859275 cites W2021338588 @default.
• W2106859275 cites W2023685327 @default.
• W2106859275 cites W2029745420 @default.
• W2106859275 cites W2040547343 @default.
• W2106859275 cites W2061647213 @default.
• W2106859275 cites W2069946049 @default.
• W2106859275 cites W2081542461 @default.
• W2106859275 cites W2082253960 @default.
• W2106859275 cites W2086332151 @default.
• W2106859275 cites W2104948944 @default.
• W2106859275 cites W2105490558 @default.
• W2106859275 cites W2106710384 @default.
• W2106859275 cites W2111588724 @default.
• W2106859275 cites W2131960841 @default.
• W2106859275 cites W2132661548 @default.
• W2106859275 cites W2135277259 @default.
• W2106859275 cites W2135403800 @default.
• W2106859275 cites W2136881506 @default.
• W2106859275 cites W2139204856 @default.
• W2106859275 cites W2150495005 @default.
• W2106859275 cites W2151491950 @default.
• W2106859275 cites W2161552221 @default.
• W2106859275 cites W2164238938 @default.
• W2106859275 cites W2164392039 @default.
• W2106859275 cites W2169604625 @default.
• W2106859275 cites W2169756025 @default.
• W2106859275 cites W2170073367 @default.
• W2106859275 doi "https://doi.org/10.1136/jmedgenet-2014-102348" @default.
• W2106859275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24748646" @default.
• W2106859275 hasPublicationYear "2014" @default.
• W2106859275 type Work @default.
• W2106859275 sameAs 2106859275 @default.
• W2106859275 citedByCount "18" @default.
• W2106859275 countsByYear W21068592752015 @default.
• W2106859275 countsByYear W21068592752016 @default.
• W2106859275 countsByYear W21068592752017 @default.
• W2106859275 countsByYear W21068592752018 @default.
• W2106859275 countsByYear W21068592752019 @default.
• W2106859275 countsByYear W21068592752020 @default.
• W2106859275 crossrefType "journal-article" @default.
• W2106859275 hasAuthorship W2106859275A5003647254 @default.
• W2106859275 hasAuthorship W2106859275A5026572220 @default.
• W2106859275 hasAuthorship W2106859275A5029175418 @default.
• W2106859275 hasAuthorship W2106859275A5031171090 @default.
• W2106859275 hasAuthorship W2106859275A5035645353 @default.
• W2106859275 hasAuthorship W2106859275A5040342808 @default.
• W2106859275 hasAuthorship W2106859275A5042890325 @default.
• W2106859275 hasAuthorship W2106859275A5057965399 @default.
• W2106859275 hasAuthorship W2106859275A5070677379 @default.
• W2106859275 hasAuthorship W2106859275A5079962370 @default.
• W2106859275 hasAuthorship W2106859275A5084425257 @default.
• W2106859275 hasAuthorship W2106859275A5091751427 @default.
• W2106859275 hasConcept C104317684 @default.
• W2106859275 hasConcept C135763542 @default.
• W2106859275 hasConcept C147483822 @default.
• W2106859275 hasConcept C159654299 @default.
• W2106859275 hasConcept C180754005 @default.
• W2106859275 hasConcept C188280979 @default.
• W2106859275 hasConcept C203014093 @default.
• W2106859275 hasConcept C2780640218 @default.
• W2106859275 hasConcept C32611913 @default.
• W2106859275 hasConcept C40767141 @default.
• W2106859275 hasConcept C54355233 @default.
• W2106859275 hasConcept C71924100 @default.
• W2106859275 hasConcept C86803240 @default.
• W2106859275 hasConceptScore W2106859275C104317684 @default.
• W2106859275 hasConceptScore W2106859275C135763542 @default.
• W2106859275 hasConceptScore W2106859275C147483822 @default.
• W2106859275 hasConceptScore W2106859275C159654299 @default.
• W2106859275 hasConceptScore W2106859275C180754005 @default.
• W2106859275 hasConceptScore W2106859275C188280979 @default.
• W2106859275 hasConceptScore W2106859275C203014093 @default.

• next